| Literature DB >> 32597834 |
Katarzyna Bulek1,2, Junjie Zhao1, Yun Liao1, Nitish Rana3,4, Daniele Corridoni5, Agne Antanaviciute5, Xing Chen1, Han Wang1, Wen Qian1, William A Miller-Little1,3, Shadi Swaidani6, Fangqiang Tang1, Belinda B Willard7, Keith McCrae6, Zizhen Kang1, George R Dubyak4, Fabio Cominelli3,8,9, Alison Simmons5, Theresa T Pizarro3,8, Xiaoxia Li1.
Abstract
Gasdermin D (GSDMD) induces pyroptosis via the pore-forming activity of its N-terminal domain, cleaved by activated caspases associated with the release of IL-1β. Here, we report a nonpyroptotic role of full-length GSDMD in guiding the release of IL-1β-containing small extracellular vesicles (sEVs) from intestinal epithelial cells (IECs). In response to caspase-8 inflammasome activation, GSDMD, chaperoned by Cdc37/Hsp90, recruits the E3 ligase, NEDD4, to catalyze polyubiquitination of pro-IL-1β, serving as a signal for cargo loading into secretory vesicles. GSDMD and IL-1β colocalize with the exosome markers CD63 and ALIX intracellularly, and GSDMD and NEDD4 are required for release of CD63+ sEVs containing IL-1β, GSDMD, NEDD4, and caspase-8. Importantly, increased expression of epithelial-derived GSDMD is observed both in patients with inflammatory bowel disease (IBD) and those with experimental colitis. While GSDMD-dependent release of IL-1β-containing sEVs is detected in cultured colonic explants from colitic mice, GSDMD deficiency substantially attenuates disease severity, implicating GSDMD-mediated release of IL-1β sEVs in the pathogenesis of intestinal inflammation, such as that observed in IBD.Entities:
Keywords: Cytokines; Gastroenterology; Inflammation; Inflammatory bowel disease; Innate immunity
Mesh:
Substances:
Year: 2020 PMID: 32597834 PMCID: PMC7410065 DOI: 10.1172/JCI138103
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808